Benzinga | Mar 1, 2021 07:33AM EST

Biohaven Pharmaceutical Q4 EPS $(2.69) Beats $(2.97) Estimate, Sales $35.11M Beat $28.23M Estimate

Biohaven Pharmaceutical (NYSE:BHVN) reported quarterly losses of $(2.69) per share which beat the analyst consensus estimate of $(2.97) by 9.43 percent. This is a 5.61 percent increase over losses of $(2.85) per share from the same period last year. The company reported quarterly sales of $35.11 million which beat the analyst consensus estimate of $28.23 million by 24.39 percent.